Rory B Riggs
CIK 1016835 · Chief Executive Officer · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RPRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
RIDGEFIELD, NJ 07657
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CBUS | Director | 14,940,447 | $1.38 | $20.62M | $5.47M | 12 | 2026-06-04 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | Director | 0 | $131.87 | $0 | -$12.95M | 64 | 2025-04-02 |
| RPRX | Director | 405,286 | $63.67 | $25.80M | -$208.34M | 27 | 2024-02-22 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 40,059 | $9.75 | $390.6K | -$6.13M | 15 | 2021-05-28 |
Recent Filings · Page 4 of 13
121 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-15 | CBUS | — | — | $0 | EDGAR |
| 2023-06-02 | — | Mixed | +4,042,548 | $31.5K | |
| 2023-05-22 | RPRX | Notice (144) | −1,756,762 | -$59.22M | EDGAR |
| 2023-05-22 | RPRX | Sell (S) | −1,750,000 | -$57.44M | EDGAR |
| 2023-05-12 | RPRX | Conv (C) | +300,000 | $0 | EDGAR |
| 2023-04-04 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +313 | $16.9K | EDGAR |
| 2023-03-30 | RPRX | Sell (S) | −139,950 | -$5.08M | EDGAR |
| 2023-02-17 | RPRX | Conv (C) | +1,500,000 | $0 | EDGAR |
| 2023-01-03 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | +321 | $17.0K | EDGAR |
| 2022-12-13 | RPRX | Sell (S) | −60,000 | -$2.52M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.